• Aclarion announced availability of CEO Brent Ness’s shareholder letter reviewing third-quarter 2026 performance.
• Scan volumes rose 85% year over year, bringing growth for the nine months ended September 30 to 117%.
• Cash of $14.2 million provides anticipated runway into the second half of 2027, with resources to fully fund the 300-patient CLARITY trial.
• CLARITY expanded to 11 clinical sites, with revised enrollment criteria designed to accelerate recruitment.
• Overall trial duration remains on track; an update on enrollment progress and anticipated initial readout timing is expected by year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200700PRIMZONEFULLFEED9849363) on October 20, 2026, and is solely responsible for the information contained therein.